Abstract A41: Small molecule inhibition of PTPN2/1 inflames the tumour microenvironment and unleashes potent CD8+ T cell immunity

Hakimeh Ebrahimi-Nik(Broad Institute), Robert T. Manguso(Broad Institute), Melissa M. Ronan(Broad Institute), Omar I. Avila(Broad Institute), Andrew S. Boghossian(University of California, San Francisco), James C. Patti(Broad Institute), Rebecca Mathew(AbbVie (United States)), Tyler M. Balon(Broad Institute), Arvin Iracheta‐Vellve(Broad Institute), Jennifer M. Frost(Mount Sinai Hospital), Philip R. Kym(AbbVie (United States)), Thomas R.G. Davis(Broad Institute), Carey Backus(University of Michigan), Cun Lan Chuong(Broad Institute), Meng‐Ju Wu(Broad Institute), Mitchell D. Yeary(Broad Institute), Jennifer A. Roth(Broad Institute), Ian C. Kohnle(Broad Institute), Elliot P. Farney(AbbVie (United States)), Kathleen A. McGuire(AbbVie (United States)), Clay C. Beauregard(New York Life Insurance Company (United States)), Keith M. Hamel(AbbVie (United States)), Matthew G. Rees(Broad Institute), Nabeel El-Bardeesy(Broad Institute), Kathleen B. Yates(Broad Institute), Gabriel K. Griffin(Harvard University), Kira E. Olander(Broad Institute), Zhaoming Xiong(AbbVie (United States)), Sarah Kim(University of Miami), Todd R. Golub(Broad Institute), Christina K. Baumgartner(AbbVie (United States)), Geoff T. Halvorsen(AbbVie (United States))
Cancer Immunology Research
December 1, 2022
Cited by 0


Related Papers